Drug Profile
MTL 004
Alternative Names: MTL-004Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Morvus Technology
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Skin-cancer in United Kingdom (Topical)
- 13 Jul 2016 Early research in Skin cancer in United Kingdom (Topical)